Skip to main content
Delfa

← All assets

Elenbecestat

6 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

6

Ongoing

0

Recruiting

0

Completed

4

Sites

246

Countries

18

Endpoints

116

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 116 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
4
Phase 2
1
Phase 3
1

Trials by status

Completed
4
Terminated
2

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK
32
Global cognition
26
Memory
18
Neuroimaging
12
Amyloid biomarkers
7
Other (unclassified)
7
Executive function / language
4
Disease progression
4
Function / daily living
2
Behavior / neuropsychiatric
2
Fluid / digital biomarkers
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 44 of 116 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogMemory

16

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

10

ADAS-CogCognition

8

Mini-Mental State Examination (MMSE)Cognition

8

Amyloid PET CentiloidAmyloid

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

6 of 6

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
MissionAD1A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease

Elenbecestat

Alzheimer’s disease

MCI due to AD / mild AD dementiaPh 3Terminated258Jan 20203results
NCT02322021Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

Elenbecestat

Alzheimer’s disease, MCI / preclinical Alzheimer’s

MCI due to AD / prodromal ADPh 2Terminated21Dec 2019-results
NCT02859207A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

Elenbecestat

Alzheimer’s disease

Healthy volunteersPh 1Completed3Dec 2016-
NCT01600859Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)

Elenbecestat

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Alzheimer's diseasePh 1Completed2Sep 2013-
NCT01716897An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

Elenbecestat

Alzheimer’s disease

Age 30-55Ph 1Completed1Dec 2012-
NCT01294540Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort

Elenbecestat

Alzheimer’s disease

Healthy volunteersPh 1Completed1Oct 2011-

Showing 1-6 of 6 trials